Golden State Wealth Management LLC Makes New $79,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Golden State Wealth Management LLC purchased a new stake in Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 500 shares of the medical research company’s stock, valued at approximately $79,000.

Other hedge funds also recently modified their holdings of the company. Chartwell Investment Partners LLC increased its holdings in Natera by 37.9% in the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after purchasing an additional 11,362 shares in the last quarter. Cerity Partners LLC increased its stake in shares of Natera by 27.0% in the third quarter. Cerity Partners LLC now owns 86,144 shares of the medical research company’s stock valued at $10,936,000 after buying an additional 18,316 shares during the period. Wilmington Savings Fund Society FSB acquired a new position in shares of Natera in the third quarter valued at approximately $385,000. Everence Capital Management Inc. bought a new position in Natera in the 4th quarter valued at approximately $573,000. Finally, First Turn Management LLC acquired a new stake in Natera during the 3rd quarter worth approximately $19,760,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Activity at Natera

In related news, Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction that occurred on Thursday, November 14th. The stock was sold at an average price of $158.53, for a total transaction of $350,668.36. Following the transaction, the director now owns 19,386 shares of the company’s stock, valued at $3,073,262.58. The trade was a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 4,728 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $146.41, for a total value of $692,226.48. Following the completion of the sale, the chief executive officer now directly owns 185,034 shares of the company’s stock, valued at $27,090,827.94. The trade was a 2.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 312,394 shares of company stock valued at $52,333,520. 7.60% of the stock is owned by company insiders.

Natera Price Performance

NTRA stock opened at $172.82 on Monday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The company’s 50-day moving average is $167.66 and its 200-day moving average is $140.97. The stock has a market capitalization of $22.82 billion, a PE ratio of -98.19 and a beta of 1.66. Natera, Inc. has a 1 year low of $67.33 and a 1 year high of $183.00.

Natera (NASDAQ:NTRA) last announced its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s quarterly revenue was up 63.9% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.95) earnings per share. Equities research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on NTRA. TD Cowen upped their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. increased their price objective on Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Morgan Stanley lifted their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Sanford C. Bernstein increased their price target on Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, January 10th. Finally, The Goldman Sachs Group lifted their price objective on Natera from $160.00 to $190.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $165.88.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.